Hepatitis viruses under immunosuppressive agents

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 1, 1998, Pages 14-20

  Liaw, Yun Fan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antiviral therapy; Hepatitis B virus; Hepatitis C virus; Immunosuppressants; T cell mediated immune mechanisms

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN A; DNA POLYMERASE; GLUCOCORTICOID; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; VIRUS DNA; VIRUS RNA;

CELLULAR IMMUNITY; CHRONIC HEPATITIS; CYTOTOXIC T LYMPHOCYTE; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS VIRUS; HORMONE RESPONSIVE ELEMENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; VIREMIA; VIRUS REPLICATION;

EID: 0031908717     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00539.x     Document Type: Review

References (75)

1. Ducci H, Katz R. Cortisone, ACTH and antibiotics in fulminant hepatitis. Gastroenterology 1952; 21: 357.
2. Redeker AG, Schweitzer IL, Yamahiro HS. Randomization of corticosteroid therapy in fulminant hepatitis. N. Engl. J. Med. 1976; 294: 728.
3. Schalm SW, Summerskill WHJ, Gitnick GL, Elveback LR. Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis B antigen. Gut 1976; 17: 781-6.
4. Lam KC, Lai CL, Ng RP, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N. Engl. J. Med. 1981; 304: 380-6.
5. Sagneli E, Maio G, Felaco FM et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; ii: 395-7.
6. Scullard GH, Smith CI, Merigan TC, Robison WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987-91.
7. Nair PV, Tong MJ, Stevenson D, Roskamp D, Boone C. Effects of short-term, high-dose prednisolone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 1985; 5: 8-12.
8. Sjogren MH, Hoofnagle JH, Waggoner JG. Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology 1987; 7: 582-5.
9. Ras E, Michaeli J, Rosenmann E, Popovtzer MM, Polliack A, Shouval D. Excessive hepatitis B surface antigen production after corticosteroids and the development of immunoblastic lymphoma. Leuk. Lymphoma 1993; 10: 241-4.
10. Mondelli M, Vergani GM, Alberti A et al. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. J. Immunol. 1982; 129: 2773-8.
11. Dienes HP, Hutteroth T, Hess G, Meuer SC. Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis B and non-A, non-B. Hepatology 1987; 7: 1317-25.
12. Chu CM, Shyu WC, Kuo RW, Liaw YF. HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: its role in the pathogenesis of chronic type B hepatitis. Hepatology 1987; 7: 1311-16.
13. Penna A, Chisari FV, Bertoletti A et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J. Exp. Med. 1991; 174: 1566-70.
14. Chu CM, Liaw YF. Coexpression of intercellular adhesion molecule-1 and class I major histocompatibility complex antigens on hepatocyte membrane in chronic viral hepatitis. J. Clin. Pathol. 1993; 46: 1004-8.
15. Nayershina R, Fowler P, Guilhot S et al. HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J. Immunol. 1993; 150: 4659-71.
16. Tsai SL, Chen MH, Yeh CT et al. Purification and characterization of a naturally processed hepatitis virus peptide recognized by CD8+ cytotoxic T lymphocytes. J. Clin. Invest. 1996; 97: 577-84.
17. Oefinger PH, Bronson DL, Dreesman GR. Induction of hepatitis B surface antigen in human hepatoma derived cell lines. J. Gen. Virol. 1981; 53: 105-113.
18. Clementi M, Bagnarelli P, Pauri P. Effect of steroids and adenine-arabinoside (araA) on growth and HBsAg production of human hepatoma cell line. Arch. Virol. 1983; 75: 137-41.
19. Gripon P, Diot C, Corlu A, Guguen-Guillouzo C. Regulation by dimethylsulfoxide, insulin, and corticosteroids of hepatoma cell line. J. Med. Virol. 1989; 28: 193-9.
20. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992; 16: 13-18.
21. Lau JYN, Bain VG, Smith HM, Alexander GJM, Williams R. Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture. Transplantation 1992; 53: 894-8.
22. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl Acad. Sci. USA 1986; 83: 1627-31.
23. Cote PJ, Korba BE, Steinberg H et al. Cyclosporin A modulates the course of woodchuck hepatitis virus infection and induces chronicity. J. Immunol. 1991; 146: 3138-44.
24. Cote PJ, Korba BE, Baldwin B, Hornbuckle WE, Tennant BC, Gerin JL. Immunosuppression with cyclosporine during the incubation period of experimental wood-chuck hepatitis virus infection increases the frequency of chronic infection in adult woodchuck. J. Infect. Dis. 1992; 166: 628-31.
25. Farza H, Salmon AM, Hadchouel M et al. Hepatitis B surface antigen expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc. Natl Acad. Sci. USA 1987; 84: 1187-91.
26. Yokosuda O, Omata M, Imazeki F et al. Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. A controlled study. Gastroenterology 1985; 89: 246-51.
27. Liaw YF. Current trend of therapy for chronic viral hepatitis. J. Gastroenterol. Hepatol. 1997; 12 (Suppl.): S346-53.
28. Lok ASF, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
29. Liaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: A randomized controlled trial. J. Hepatol. 1994; 20: 175-80.
30. Hanson RG, Peters MG, Hoofnagle JH. Effects of immunosuppressive therapy with prednisone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 1986; 6: 173-9.
31. Buti M, Esteban R, Esteban JI, Gonzalea A, Guardia J. Severe hepatic failure after Ara-A/prednisolone for chronic type B hepatitis. Gastroenterology 1987; 92: 274-5.
32. Laskus T, Slusarczyk J, Cianciara J, Loch T. Exacerbation of chronic active hepatitis B after short-term corticosteroid therapy resulting in fatal liver failure. Am. J. Gastroenterol. 1990; 85: 1414-17.
33. Pariente EA, Goudeau A, Dubois F et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig. Dis. Sci. 1988; 33: 1185-91.
34. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990; 65: 878-84.
35. Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. J. Gastroenterol. Hepatol. 1996; 11: 143-7.
36. Demetris AJ, Todo S, Van Thiel DH et al. Evolution of hepatitis B virus liver disease after hepatic replacement: practical and theoretical considerations. Am J. Pathol. 1990; 137: 667-76.
37. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation: serological and clinical implications. J. Hepatol. 1992; 14: 104-11.
38. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993; 329: 1842-7.
39. Angus PW, Locarnini SA, McCaughan GW, Jones RM, McMillan JS, Bowder DS. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995; 21: 14-18.
40. Lau JYN, Bain VG, Davies SE et al. High level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102: 956-62.
41. Hung YB, Liang JT, Chu JS, Chen KM, Lee CS. Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigen: A case report of fibrosing cholestatic hepatitis. Hepatogastroenterology 1995; 42: 913-18.
42. McIvor C, Morton J, Bryant A, Cooksley G, Durrant S, Walker N. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann. Intern. Med. 1994; 121: 274-5.
43. Daikoku M, Nakata K, Hamasaki K et al. Analysis of wild type and e antigen defective hepatitis B viruses during the course of a short-term corticosteroid therapy in chronic hepatitis B. J. Med. Virol. 1995; 47: 184-8.
44. Protzer U, Goergen B, Hopf U et al. Pre-core mutants of hepatitis B virus in patients receiving immunosuppressive treatment after orthotopic liver transplantation. J. Med. Virol. 1996; 50: 135-44.
45. Karayiannis P, Goldin R, Luther S, Carman WF, Monjardino J, Thomas HC. Effect of cyclosporin-A in woodchucks with chronic hepatitis delta virus infection. J. Med. Virol. 1992; 36: 316-21.
46. Samuel D, Zignego AL, Reynes M et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-9.
47. Botarelli P, Brunetto MR, Minutello MA et al. T-lymphocyte responses to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104: 580-7.
48. Kita H, Moriyama T, Kaneko T et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993; 18: 1039-44.
49. Erickson AL, Houghton M, Choo QL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J. Immunol. 1993; 151: 4189-99.
50. Koziel MJ, Duddley D, Afdhal N et al. Hepatitis C virus (HCV) specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J. Virol. 1993; 67: 7522-32.
51. Liaw YF, Lee CS, Tsai SL et al T-cell mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995; 22: 1368-73.
52. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567-71.
53. Mondelli M, Alberti A, Tremolada F, Williams R, Eddleston ALWF, Realdi G. In vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis. Clin. Exp. Immunol. 1986; 63: 147-55.
54. Liaw YF, Sheen IS, Lin SM, Chen TJ, Chu CM. Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. Liver 1993; 13: 46-50.
55. Fong TL, Valialuck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisolone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196-9.
56. Chayama K, Tsubota A, Kobayashi M et al. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology 1996; 23: 953-7.
57. Krawczynski K. Immunopathogenesis of HCV infection: An overview of experimental studies. Second International Hepatitis C Conference. San Diego: 1994; 124 (Abstract).
58. Kakumu S, Takayanagi M, Iwata K et al. Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. J. Gastroenterol. Hepatol. 1997; 12: 62-6.
59. Orito E, Mizokami M, Nakamo T et al. Serum hepatitis C virus RNA levels as a predictor of subsequent response to interferon-α therapy in Japanese patients with chronic hepatitis C. J. Med. Virol. 1994; 44: 410-14.
60. Magrin S, Craxi A, Fabiano C et al. Hepatitis C viremia in chronic liver disease: Relationship to interferon-a or corticosteroid treatment. Hepatology 1994; 19: 273-9.
61. Chazouilleres O, Wright TL. Hepatitis C and liver transplantation. J. Gastroenterol. Hepatol. 1995; 10: 471-80.
62. Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-4.
63. Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: Association with rejection and increased immunosuppression after transplantation. Surgery 1995; 119: 452-6.
64. Chazouilleres O, Kim M, Combs C et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994-9.
65. Feray C, Gigou M, Samuel D et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137-43.
66. Gane EJ, Naoumov NV, Qian KP et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-77.
67. Gretch DR, Bacchi CE, Corey L et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22: 1-9.
68. Lim HL, Lau GK, Davis GL, Dolson DJ, Lau JYN. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C infection. Gastroenterology 1994; 106: 248-51.
69. Lau JYN, Davis GL, Brunson ME et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993; 18: 1027-31.
70. Roth D, Zucker K, Cirocco R et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 6 886-9.
71. Kanamori H, Fukawa H, Maruta A et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am. J. Med. Sci. 1992; 303: 109-11.
72. Gruber A, Lundberg LG, Björkholm M. Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. J. Intern. Med. 1993; 234: 223-5.
73. Vento S, Cainelli F, Mirandola F et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347: 92-3.
74. McDonald GSA, Courtney MG, Shatrock AG, Weir DG. Prolonged IgM antibodies and histopathological evidence of chronicity in hepatitis A. Liver 1989; 9: 223-8.
75. Liaw YF. Chronic hepatitis caused by the hepatitis A virus. Hepatology 1990; 11: 1089-90.